- Home
- Publications
- Publication Search
- Publication Details
Title
Antiviral therapy for chronic hepatitis C in 2014
Authors
Keywords
-
Journal
Expert Review of Clinical Pharmacology
Volume 7, Issue 4, Pages 499-505
Publisher
Informa UK Limited
Online
2014-06-18
DOI
10.1586/17512433.2014.915737
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
- (2014) Mark S. Sulkowski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1
- (2014) Kris V. Kowdley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Danoprevir-Ritonavir plus Peginterferon Alfa-2a–Ribavirin in Hepatitis C Virus Genotype 1 Prior Null Responders
- (2013) Edward J. Gane et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Faldaprevir (BI 201335), BI 207127 and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results
- (2013) Stefan Zeuzem et al. ANTIVIRAL THERAPY
- Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection
- (2013) Maribel Rodríguez-Torres Expert Review of Anti-Infective Therapy
- Randomized Controlled Trial of Danoprevir Plus Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve Patients With Hepatitis C Virus Genotype 1 Infection
- (2013) Patrick Marcellin et al. GASTROENTEROLOGY
- Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial
- (2013) Stefan Zeuzem et al. GASTROENTEROLOGY
- Eradication of hepatitis C infection: The importance of targeting people who inject drugs
- (2013) Margaret Hellard et al. HEPATOLOGY
- Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study
- (2013) Michael W. Fried et al. HEPATOLOGY
- JUMP-C: A randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients
- (2013) Paul J. Pockros et al. HEPATOLOGY
- Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype1 HCV: SILEN-C1 trial
- (2013) Mark S. Sulkowski et al. HEPATOLOGY
- PROPEL: A randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients
- (2013) Heiner Wedemeyer et al. HEPATOLOGY
- Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial
- (2013) Mark S. Sulkowski et al. HEPATOLOGY
- Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders
- (2013) Anna S. Lok et al. JOURNAL OF HEPATOLOGY
- Minimal impact of sofosbuvir and ribavirin on health related quality of life in Chronic Hepatitis C (CH-C)
- (2013) Zobair M. Younossi et al. JOURNAL OF HEPATOLOGY
- Discovery of Danoprevir (ITMN-191/R7227), a Highly Selective and Potent Inhibitor of Hepatitis C Virus (HCV) NS3/4A Protease
- (2013) Yutong Jiang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus Infection
- (2013) John O. Link et al. JOURNAL OF MEDICINAL CHEMISTRY
- Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3
- (2013) E. B. Tapper et al. JOURNAL OF VIRAL HEPATITIS
- Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
- (2013) Eric Lawitz et al. LANCET
- Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
- (2013) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
- (2013) Edward J. Gane et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of HCV Infection by Targeting MicroRNA
- (2013) Harry L.A. Janssen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
- (2013) Eric Lawitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Miravirsen (SPC3649) can inhibit the biogenesis of miR-122
- (2013) Luca F. R. Gebert et al. NUCLEIC ACIDS RESEARCH
- Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: A population and clonal analysis
- (2013) Richard J.O. Barnard et al. VIROLOGY
- Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives
- (2013) Kazi Abdus Salam et al. Biomed Research International
- MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants
- (2012) Vincenzo Summa et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
- (2012) Anna S. Lok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Discovery of Vaniprevir (MK-7009), a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor
- (2010) John A. McCauley et al. JOURNAL OF MEDICINAL CHEMISTRY
- GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796
- (2009) M. F. McCown et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation